Clinical Trial

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, open-label, randomized phase II clinical trial designed to compare the efficacy and toxicity of hypofractionated concurrent chemoradiotherapy versus conventional fractionated concurrent chemoradiotherapy following induction chemoimmunotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-28; most recent amendment 2025-11-13.
Trial Details
NCT Number NCT06912074
Lead Sponsor Sun Yat-sen University
Conditions Esophageal Squamous Cell Carcinoma (ESCC)
Enrollment 134 participants
Start Date 2025-04-05
Primary Completion 2029-04-04 (estimated)
Study Completion 2029-04-04 (estimated)
Updated on ClinicalTrials.gov 2025-11-17